Cancer Immunotherapy Market is Growing at a CAGR of 12.6% from 2021 to 2030: New Report Study

Cancer Immunotherapy Market size is expected to reach over USD 277.1 billion by 2030 from at USD 85 billion in 2021, growing at a CAGR of 12.6% from 2021 to 2030.

Get the sample pages of report@ https://www.precedenceresearch.com/sample/1394

Growth Factors

The rising prevalence of various cancer such as colorectal cancer, bowel cancer, breast cancer, and lungs cancer among the global population and rising adoption of the immunotherapy to treat cancer is boosting the growth of the global cancer immunotherapy market. The rising awareness regarding the advantages of the cancer immunotherapy over the conventional chemotherapies is further driving the demand for the cancer immunotherapy among the cancer patients. The rising disposable income, availability of advanced healthcare facilities, and rising consumer expenditure on healthcare is positively impacting the growth of the global cancer immunotherapy market. Cancer Immunotherapy has less side effects and have long term treatment affects, which boosts the demand for the cancer immunotherapy across the globe.

Report Highlights

• Based on the technology type, the monoclonal antibodies segment dominated the market in 2020. Monoclonal antibodies specifically target the effected cells and helps in the better treatment. Moreover, the less toxicity and low risks of side-effects as it does not affects the normal cells is a major factor that boosted the demand for the monoclonal antibodies across the globe.
• Based on the application, the breast cancer segment is estimated to be the most opportunistic segment during the forecast period. The rapidly growing cases of breast cancer among the global women population is the primary factor behind this. According to the International Agency for Cancer Research, breast cancer has become the most diagnosed type of cancer across the globe and this alarming rise in the growth rate of breast cancer is anticipated to boost this segment.
• Based on the end user, the hospitals segment dominated the market in 2020. The rising number of hospital admissions owing to the surging growth in the number of cancer cases and deaths has boosted the growth of this growth. The rising government expenditure on the development of the healthcare infrastructure especially in the developed nations is further expected to fuel the market growth.

Ask here for customization study@ https://www.precedenceresearch.com/customization/1394

Regional Snapshot

North America dominated the global cancer immunotherapy market in 2020. This is primarily due to the increased prevalence of cancer in the region. According to the American Cancer Society, over 1.8 million new cancer cases and 606,520 deaths were reported in the US in 2020. The lungs cancer, colorectal cancer, breast cancer, and prostate cancer are the top four cancers that prevails in the US. Further, the increased disposable income, increased awareness regarding the benefits of the cancer immunotherapy among the population, and presence of strong and advanced healthcare infrastructure in the region is augmenting the market growth.

Europe is estimated to be the fastest-growing market during the forecast period. The high disposable income, rising healthcare expenditure, and rising awareness regarding the cancer immunotherapy is expected to drive the market growth in this region. Further, rising cancer cases and cancer deaths in the region is further fueling the market growth.According to the European Commission, around 2.7 million new cancer cases and around 1.3 million cancer deaths were reported in 2020. The geriatric population of aged 65 years or above were the most affected by cancer in Europe. Breast cancer has been recorded as the most diagnosed cancers across the European countries in 2020.

OBJECTIVES OF THE STUDY

• To analyze and forecast the Cancer Immunotherapy market, in terms of value and volume
• To provide information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
• To define, segment, and project the size of the global Cancer Immunotherapy market on the product type, end-use and other segments
• To project the size of the market, with respect to five main regions, namely, North America, Europe, Asia Pacific (APAC), the Middle East & Africa, and South America, with their key countries
• To strategically analyze micromarkets with respect to individual growth trends, growth prospects, and their contribution to the total market
• To analyze opportunities in the market for stakeholders and provide a competitive landscape of the market leaders
• To strategically profile key players and comprehensively analyze their core competencies
• To track and analyze research & development (R&D) and competitive developments such as joint ventures, mergers & acquisitions, and new product developments in the Cancer Immunotherapy market

Research Methodology

• Market estimate for 2021
• Average selling price (ASP) per region for specific product type
• Filtrations and assortment of gathered data, to estimate the base year (2021) market size for the country
• Gathering data from company websites, annual reports, white papers, financial reports, broker reports, investor presentations, and SEC filings
• National government documents, statistical databases
• News articles, press releases, and webcasts specific to companies operating in the market
• Country wise analysis through internal and external proprietary databases, and relevant patent and regulatory databases
• Determination of market penetration by country

Major Players Covered in this Report

The updated market research report on Cancer Immunotherapy market allows the buyers and manufacturers to stay updated with the current market trends, ongoing happenings, and a clear picture on the market scenario. List of key players included in the research report will help the market vendors to know their market position and plan more operational strategies to gain topmost position among other players. The report offers crucial company information on each market player, such as company profile, financial information, and recently adopted growth strategies. This will help other existing players and the new entrants to plan strategies and establish their presence in the market.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

• Company Overview
• Company Market Share/Positioning Analysis
• Product Offerings
• Financial Performance
• Recent Initiatives
• Key Strategies Adopted by Players
• Vendor Landscape
• List of Suppliers
• List of Buyers

Segments Covered in the Report

By Technology Type

• Monoclonal Antibodies
• Cytokines & Immunomodulators
• Checkpoint Inhibitors
• Others

By Cancer Type

• Lungs Cancer
• Colorectal Cancer
• Melanoma
• Breast Cancer
• Head & Neck Cancer
• Prostate Cancer
• Others

By End User

• Hospitals
• Clinics
• Cancer Research Centers

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
• Rest of the World

Table of Contents

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Immunotherapy Market 

5.1. COVID-19 Landscape: Cancer Immunotherapy Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Immunotherapy Market, By Technology

8.1. Cancer Immunotherapy Market, by Technology Type, 2021-2030

8.1.1. Monoclonal Antibodies

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Cytokines & Immunomodulators

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Checkpoint Inhibitors

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Cancer Immunotherapy Market, By Cancer

9.1. Cancer Immunotherapy Market, by Cancer, 2021-2030

9.1.1. Lungs Cancer

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Colorectal Cancer

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Melanoma

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Breast Cancer

9.1.4.1. Market Revenue and Forecast (2019-2030)

9.1.5. Head & Neck Cancer

9.1.5.1. Market Revenue and Forecast (2019-2030)

9.1.6. Prostate Cancer

9.1.6.1. Market Revenue and Forecast (2019-2030)

9.1.7. Others

9.1.7.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Cancer Immunotherapy Market, By End User 

10.1. Cancer Immunotherapy Market, by End User, 2021-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Clinics

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Cancer Research Centers

10.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Cancer Immunotherapy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Technology (2019-2030)

11.1.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.1.3. Market Revenue and Forecast, by End User (2019-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.1.4.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.1.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.1.5.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.1.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.2.3. Market Revenue and Forecast, by End User (2019-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.4.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.2.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.5.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.2.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.6.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.2.6.3. Market Revenue and Forecast, by End User (2019-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Technology (2019-2030)

11.2.7.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.2.7.3. Market Revenue and Forecast, by End User (2019-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.3.3. Market Revenue and Forecast, by End User (2019-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.4.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.3.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.5.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.3.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.6.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.3.6.3. Market Revenue and Forecast, by End User (2019-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Technology (2019-2030)

11.3.7.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.3.7.3. Market Revenue and Forecast, by End User (2019-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.4.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.4.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.5.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.4.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.6.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.4.6.3. Market Revenue and Forecast, by End User (2019-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Technology (2019-2030)

11.4.7.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.4.7.3. Market Revenue and Forecast, by End User (2019-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.5.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.5.3. Market Revenue and Forecast, by End User (2019-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Technology (2019-2030)

11.5.4.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.5.4.3. Market Revenue and Forecast, by End User (2019-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Technology (2019-2030)

11.5.5.2. Market Revenue and Forecast, by Cancer (2019-2030)

11.5.5.3. Market Revenue and Forecast, by End User (2019-2030)

Chapter 12. Company Profiles

12.1. Amgen, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Astrazeneca, PLC

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Bayer AG

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Bristol-Myers Squibb Company

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Eli Lily And Company

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. F. Hoffmann-La Roche, Ltd

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Pfizer, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Johnson & Johnson

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Merck KGAA

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Novartis AG

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Buy this Research Report study@ https://www.precedenceresearch.com/checkout/1394

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333